全文获取类型
收费全文 | 9077篇 |
免费 | 590篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 127篇 |
儿科学 | 364篇 |
妇产科学 | 232篇 |
基础医学 | 1193篇 |
口腔科学 | 348篇 |
临床医学 | 615篇 |
内科学 | 2216篇 |
皮肤病学 | 246篇 |
神经病学 | 725篇 |
特种医学 | 394篇 |
外科学 | 1317篇 |
综合类 | 33篇 |
一般理论 | 2篇 |
预防医学 | 736篇 |
眼科学 | 180篇 |
药学 | 443篇 |
中国医学 | 47篇 |
肿瘤学 | 481篇 |
出版年
2023年 | 54篇 |
2022年 | 49篇 |
2021年 | 341篇 |
2020年 | 188篇 |
2019年 | 299篇 |
2018年 | 356篇 |
2017年 | 223篇 |
2016年 | 204篇 |
2015年 | 272篇 |
2014年 | 339篇 |
2013年 | 440篇 |
2012年 | 672篇 |
2011年 | 682篇 |
2010年 | 399篇 |
2009年 | 331篇 |
2008年 | 517篇 |
2007年 | 514篇 |
2006年 | 494篇 |
2005年 | 442篇 |
2004年 | 416篇 |
2003年 | 397篇 |
2002年 | 365篇 |
2001年 | 225篇 |
2000年 | 215篇 |
1999年 | 218篇 |
1998年 | 64篇 |
1997年 | 69篇 |
1996年 | 50篇 |
1995年 | 45篇 |
1994年 | 27篇 |
1993年 | 33篇 |
1992年 | 70篇 |
1991年 | 69篇 |
1990年 | 75篇 |
1989年 | 60篇 |
1988年 | 55篇 |
1987年 | 65篇 |
1986年 | 44篇 |
1985年 | 37篇 |
1984年 | 25篇 |
1983年 | 25篇 |
1982年 | 13篇 |
1981年 | 13篇 |
1979年 | 31篇 |
1977年 | 16篇 |
1976年 | 18篇 |
1974年 | 13篇 |
1973年 | 12篇 |
1972年 | 13篇 |
1967年 | 13篇 |
排序方式: 共有9699条查询结果,搜索用时 15 毫秒
21.
M. L. Vizuete M. Santiago A. J. Herrera J. L. Venero A. Machado J. Cano 《Journal of neural transmission (Vienna, Austria : 1996)》1991,85(3):231-242
Summary Levels of dopamine (DA), noradrenaline (NA) and 5-hydroxytryptamine (serotonin, 5-HT) and their metabolites, and the activities of tyrosine hydroxylase (TH), tryptophan hydroxylase (TPH) and monoamine oxidase A and B (MAO-A and MAO-B) have been determined in the rat posterior thalamus after enucleation during postnatal development. DA and 5-HT turnover rate have been measured as 3,4-dihydroxyphenylalanine (DOPA) and 5-hydroxytryptophan (5-HTP) accumulation rates after central decarboxylase inhibition by 3-hydroxybenzylhydrazine (NSD-1015). The major changes were an increase in noradrenergic and serotoninergic metabolism in enucleated animals compared with control animals. A decrease of the MAO-A to MAO-B ratio during postnatal development was found.Abbreviations
DA
dopamine
-
DOPAC
3,4-dihydroxyphenylacetic acid
-
HVA
homovanillic acid
-
DOPA
3,4-dihydroxyphenylalanine
-
NA
noradrenaline
-
MHPG
3-methoxy-4-hydroxyphenylgly-col
-
NMN
normetanephrine
-
TRP
tryptophan
-
5-HTP
5-hydroxytryptophan
-
5-HT
serotonin
-
5-HIAA
5-hydroxy-3-indolacetic acid
-
TH
tyrosine hydroxylase
-
TPH
tryptophan hydroxylase
-
MAO-A
monoamine oxidase-A
-
MAO-B
monoamine oxidase-B
Recipients of fellowships from I.I.E. del FISS Reincorporación de doctores y tecnólogos del M.E.C., and Perfeccionamiento de doctores y tecnólogos del MEC, Spain 相似文献
22.
23.
Ana Ortega Ph.D. George Dranitsaris M.Sci.Phm. Jeremy Sturgeon M.D. Heather Sutherland M.Sci. Amit Oza M.D. 《Gynecologic oncology》1997,66(3):454-463
The standard treatment for patients with advanced ovarian cancer (AOC) has been cyclophosphamide and cisplatin (CP). Recently, the results of a large randomized comparative trial demonstrated that the combination of paclitaxel and cisplatin (TP) provided a progression-free survival benefit of 5 months. In this study, a cost–utility analysis was performed from a Canadian health care system perspective to estimate the incremental cost-effectiveness of the TP combination. Twelve AOC patients who received treatment with TP were matched for age and disease stage on a 1-to-2 basis with a CP control. Total hospital resource consumption was then collected for all patients. Treatment preferences were estimated from a cohort of 20 patients and 40 healthy female volunteers using the time trade-off technique. The outcomes were then generated through a decision-analytic model. First-line treatment costs with TP were approximately fourfold greater on a per-cycle basis than the CP alternative (Can$1911 vs Can$459). When progression-free survival benefit and patient treatment preferences were incorporated into the analysis, the results of the decision model revealed an incremental cost between Can$12,000 and Can$24,000 per quality-adjusted progression-free year with the TP protocol. Even though the TP combination has a considerably higher drug acquisition cost, the results of the current analysis suggest that this new chemotherapy regimen does provide patients with substantial quality-adjusted progression-free survival benefit at a reasonable cost to the Canadian health care system. 相似文献
24.
Dominick Sabatino Santiago Martinez Rosemarie Young Howard Balbi Peter Ciminera Marianne Frieri 《Pediatric hematology and oncology》1991,8(4):355-359
The case of a 7-year-old girl with acquired immunodeficiency syndrome treated for 5 years with AZT and intravenous gamma globulin is reported. Shortly before her demise she developed a pulmonary leiomyosarcoma and leiomyoma. Does prolonged survival in pediatric acquired immune deficiency syndrome increase the incidence of secondary malignancies? 相似文献
25.
26.
27.
Objective To describe dislocation of the elbow with articular fracture of the distal humerus,a type of elbow fracture-dislocation about which little has been written.Methods Four patients with a dislocation of the elbow and fracture of the distal humerus were identified.Three had dislocation and complex intraarticular fracture of the capitellum,trochlea,and lateral epicondyle.Results Two patients(one treated with a second operation to address avascular necrosis of the capitellum)achieved a functional arc of elbow motion and one patient was lost after removal of the implants 3 months after fracture with documented healing.The fourth patient had a complex open fracture dislocation involving the entire articular surface.An attempt to salvage the articular surface resulted in deep infection.Extensive heterotopic bone led to arthrodesis of the elbow.Conclusions Dislocations of the elbow with articular fracture of the humerus are uncommon.Most injuries involve the capitellum,lateral trochlea,and lateral epicondyle.Open reduction and internal fixation of the distal humerus fracture can restore stability without repairing the medial collateral ligament. 相似文献
28.
We have isolated an H-2 deficient cell line (LR.4) from the T-cell lymphoma L5178Y which grew without restrictions in the peritoneal cavity of different inbred strains of mice. The use of polyclonal anti-H-2 antiserum and complement indicated that LR.4 cells did not express class I determinants on the cell membrane. Southern blots of genomic DNA of LR.4 cells showed that B2m genes were severely damaged and that class I H-2 genes were extensively methylated. Consequently, LR.4 cells failed to transcribe mRNAs for both B2m and class I H-2 genes. On the other hand, specific immunity to LR.4 was demonstrated in C57BL/6J mice since, in subsequent challenges with either LR.4 or EL4.4, LR.4 did not grow, whereas EL4.4 grew and killed the mice. In C57BL/6J mice, rejection of LR.4 was accompanied by the production of cytotoxic antibodies. The immune response induced in C57BL/6J mice was determined by non-H-2 antigenic determinants in LR.4 cells. 相似文献
29.
J M Santiago 《Hospital & community psychiatry》1992,43(11):1095-1099
In the second part of a two-part paper, the three major proposals for U.S. health care reform--the government-sponsored model, the employment-based model, and the market reform model--are reviewed. Barriers to their success include the current economic crisis, the lack of a clear consensus, and the high costs of the proposals. Most proposals limit the extent of psychiatric coverage; some exclude such coverage from minimum benefit packages, an area of concern for clinicians. The author concludes that any substantial health care reform is unlikely in the near future. A thoughtful, realistic, and yet vigorous strategic plan is needed now to forestall the possible exclusion of significant mental health coverage. The basic elements of such a plan are reviewed. 相似文献
30.
Submassive hepatic necrosis associated with the use of progabide: A GABA receptor agonist 总被引:2,自引:0,他引:2
Santiago J. Munoz MD Ruggero Fariello MD Willis C. Maddrey MD 《Digestive diseases and sciences》1988,33(3):375-380
Progabide, a recently introduced gamma-aminobutyric acid mimetic, is currently undergoing clinical evaluation for a variety of convulsive disorders. We describe a patient in whom severe hepatic failure developed after four weeks of Progabide therapy. The patient's course was marked by encephalopathy, jaundice, hypoglycemia, markedly elevated serum aminotransferase levels, and prolongation of the prothrombin time. Liver biopsy showed extensive hepatocellular necrosis. The patient recovered slowly after discontinuation of the drug. The finding of eosinophilia and increased serum IgE suggests an immunologically mediated mechanism for the Progabide-induced hepatic injury. Alternatively, the lipophilic moiety of Progabide may interact with hepatocyte cell membrane lipids leading to toxic injury. We conclude that Progabide may occasionally cause severe hepatic injury. 相似文献